QHSLab Secures Grant Sponsorship from a Global Leader in Consumer Health to Advance Digital Medicine Tools for Allergy Management in the Primary Care Setting
QHSLab, Inc. (OTCQB: USAQ) has secured a $297,360 grant sponsorship from a Global Leader in Consumer Health to fund a study on improving allergic rhinitis management in primary care using digital medicine tools. The study, titled "Harnessing Digital Medicine Tools for Improving Allergic Rhinitis Control in the Primary Care Setting," aims to validate QHSLab's Allergy Management Evaluation (AME) and Allergic Rhinitis Intervention Steps (ARIS) tools.
Led by Principal Investigator Dr. Marcos Sanchez-Gonzalez, the research will explore the effectiveness of these digital tools in providing personalized care recommendations and enhancing patient outcomes. The study has been registered on ClinicalTrials.gov with the identifier NCT06603935. This collaboration aligns with both companies' goals of leveraging technology to improve patient self-care and support healthcare providers in delivering evidence-based treatments for allergic rhinitis.
QHSLab, Inc. (OTCQB: USAQ) ha ottenuto un contributo di sponsorizzazione di $297.360 da un Leader Globale nella Salute dei Consumatori per finanziare uno studio volto a migliorare la gestione della rinite allergica nelle cure primarie attraverso l'uso di strumenti di medicina digitale. Lo studio, intitolato "Sfruttare gli Strumenti di Medicina Digitale per Migliorare il Controllo della Rinite Allergica nell'Ambito delle Cure Primarie," mira a convalidare gli strumenti di Valutazione della Gestione Allergica (AME) e i Passi di Intervento per la Rinite Allergica (ARIS) di QHSLab.
Diretto dal Ricercatore Principale Dr. Marcos Sanchez-Gonzalez, la ricerca esplorerà l'efficacia di questi strumenti digitali nel fornire raccomandazioni di cura personalizzate e nel migliorare i risultati per i pazienti. Lo studio è stato registrato su ClinicalTrials.gov con l'identificativo NCT06603935. Questa collaborazione si allinea con gli obiettivi di entrambe le aziende di sfruttare la tecnologia per migliorare l'auto-cura dei pazienti e sostenere i fornitori di servizi sanitari nel fornire trattamenti basati su evidenze per la rinite allergica.
QHSLab, Inc. (OTCQB: USAQ) ha asegurado un patrocinio de subvención de $297,360 de un Líder Global en Salud del Consumidor para financiar un estudio sobre la mejora de la gestión de la rinitis alérgica en la atención primaria utilizando herramientas de medicina digital. El estudio, titulado "Aprovechando las Herramientas de Medicina Digital para Mejorar el Control de la Rinitis Alérgica en el Entorno de Atención Primaria," tiene como objetivo validar las herramientas de Evaluación de Gestión de Alergias (AME) y Pasos de Intervención para la Rinitis Alérgica (ARIS) de QHSLab.
Dirigida por el Investigador Principal Dr. Marcos Sanchez-Gonzalez, la investigación explorará la efectividad de estas herramientas digitales en la provisión de recomendaciones personalizadas de atención y en la mejora de los resultados para los pacientes. El estudio ha sido registrado en ClinicalTrials.gov con el identificador NCT06603935. Esta colaboración se alinea con los objetivos de ambas compañías de aprovechar la tecnología para mejorar el autocuidado de los pacientes y apoyar a los proveedores de salud en la entrega de tratamientos basados en evidencia para la rinitis alérgica.
QHSLab, Inc. (OTCQB: USAQ)는 소비자 건강 분야의 글로벌 리더로부터 $297,360의 보조금 후원을 받았습니다. 이 자금은 디지털 의료 도구를 사용하여 1차 진료에서 알레르기 비염 관리 개선에 대한 연구를 지원하기 위한 것입니다. "1차 진료 환경에서 알레르기 비염 관리를 개선하기 위한 디지털 의료 도구 활용"이라는 제목의 이 연구는 QHSLab의 알레르기 관리 평가(AME) 및 알레르기 비염 개입 단계(ARIS) 도구를 검증하는 것을 목표로 하고 있습니다.
주 연구자인 Marcos Sanchez-Gonzalez 박사가 이끄는 이 연구는 이러한 디지털 도구가 맞춤형 치료 권장 사항을 제공하고 환자 결과를 향상시키는 데 효과적인지 탐구할 것입니다. 이 연구는 ClinicalTrials.gov에 NCT06603935 식별자로 등록되어 있습니다. 이번 협업은 기술을 활용하여 환자의 자기 관리 개선과 의료 제공자가 알레르기 비염에 대한 근거 기반 치료를 제공하는 지원을 강화하려는 두 회사의 목표와 일치합니다.
QHSLab, Inc. (OTCQB: USAQ) a obtenu un financement de subvention de 297 360 $ d'un leader mondial dans le domaine de la santé des consommateurs pour financer une étude sur l'amélioration de la gestion de la rhinite allergique en soins primaires à l'aide d'outils de médecine numérique. L'étude, intitulée "Exploitation des Outils de Médecine Numérique pour Améliorer le Contrôle de la Rinite Allergique en Soins Primaires," vise à valider les outils d'Évaluation de la Gestion des Allergies (AME) et les Étapes d'Intervention pour la Rinite Allergique (ARIS) de QHSLab.
Dirigée par le Chercheur Principal Dr. Marcos Sanchez-Gonzalez, la recherche explorera l'efficacité de ces outils numériques pour fournir des recommandations de soins personnalisés et améliorer les résultats des patients. L'étude a été enregistrée sur ClinicalTrials.gov avec l'identifiant NCT06603935. Cette collaboration s'inscrit dans les objectifs des deux entreprises de tirer parti de la technologie pour améliorer l'autogestion des patients et soutenir les prestataires de soins de santé dans la délivrance de traitements fondés sur des preuves pour la rhinite allergique.
QHSLab, Inc. (OTCQB: USAQ) hat eine Förderung in Höhe von $297.360 von einem Globalen Marktführer im Bereich Verbrauchergesundheit erhalten, um eine Studie zur Verbesserung des Managements von allergischer Rhinitis in der Primärversorgung mit digitalen Medizinwerkzeugen zu finanzieren. Die Studie mit dem Titel "Nutzung digitaler Medizinwerkzeuge zur Verbesserung der Kontrolle der allergischen Rhinitis im Bereich der Primärversorgung" hat zum Ziel, die Allegeriemanagementbewertung (AME) und die Interventionselemente für allergische Rhinitis (ARIS) Werkzeuge von QHSLab zu validieren.
Unter der Leitung des Hauptforschers Dr. Marcos Sanchez-Gonzalez wird die Forschung die Wirksamkeit dieser digitalen Werkzeuge untersuchen, um personalisierte Pflegeempfehlungen bereitzustellen und die Patientenergebnisse zu verbessern. Die Studie wurde unter der Kennung NCT06603935 bei ClinicalTrials.gov registriert. Diese Zusammenarbeit steht im Einklang mit den Zielen beider Unternehmen, Technologie zu nutzen, um die Selbstversorgung der Patienten zu verbessern und Gesundheitsdienstleistern bei der Bereitstellung evidenzbasierter Behandlungen für allergische Rhinitis zu unterstützen.
- Secured $297,360 grant sponsorship from a Global Leader in Consumer Health
- Study aims to validate QHSLab's digital tools for allergic rhinitis management
- Collaboration with a major consumer health company may lead to wider adoption of QHSLab's technology
- Research registered on ClinicalTrials.gov, adding credibility to the study
- None.
WEST PALM BEACH, FL, Sept. 25, 2024 (GLOBE NEWSWIRE) -- QHSLab, Inc. (the "Company") (OTCQB: USAQ), a leader in digital health and point-of-care technologies designed to empower clinicians with proactive, value-based healthcare solutions, is proud to announce a significant grant sponsorship from a Global Leader in Consumer Health. This
The collaborative agreement between QHSLab and the Global Leader in Consumer Health reflects a shared commitment to leveraging cutting-edge technology to enhance patient self-care. This partnership aligns with the sponsor’s strategic focus on utilizing innovation and scientific expertise to meet unmet healthcare needs, ensuring that the latest advancements in digital health reach both patients and healthcare providers.
"We are honored to receive this supportive grant from a Global Leader in Consumer Health, a company that shares our dedication to utilizing digital health technologies to make a measurable difference in patient outcomes," said Troy Grogan, CEO of QHSLab. "This collaboration empowers us to further validate our digital tools in real-world clinical settings, equipping healthcare providers with the resources they need to deliver personalized, evidence-based treatments for allergic rhinitis. We anticipate our research will underscore the transformative potential of digital medicine in primary care, ultimately benefiting countless patients."
Under the scientific leadership of Marcos Sanchez-Gonzalez, MD, PhD, Principal Investigator, the study will explore the effectiveness of QHSLab's Allergy Management Evaluation (AME) and Allergic Rhinitis Intervention Steps (ARIS) tools. "Allergic rhinitis remains a prevalent yet underdiagnosed condition," said Dr. Sanchez-Gonzalez. "By seamlessly integrating digital tools into routine care, we aim to provide both patients and healthcare providers with enhanced information and management strategies. This research is designed not only to improve symptom control but also to enhance patients' quality of life, satisfaction, and reduce overall healthcare costs."
QHSLab’s digital platform, including tools such as AME and ARIS, is engineered to provide healthcare providers comprehensive data on patient symptoms, treatment adherence, and overall health. The platform's AI-driven algorithms and intuitive interface ensure that patients receive timely, personalized care recommendations, promoting more effective management of their conditions. This study will play a key role in demonstrating the clinical and economic benefits of these tools, paving the way for their wider adoption across healthcare systems.
Additionally, QHSLab is proud to announce that the study titled Harnessing Digital Medicine to Improve Allergic Rhinitis Management in Primary Care (DMAR), Protocol Record QHSLab 002-24, has been officially registered NCT06603935 and publicly available at ClinicalTrials.gov.
For more information about QHSLab and its digital health solutions, please visit qhslab.com/research.
About QHSLab, Inc.
QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patient responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients’ vital signs and evaluate the effects of prescribed medicines and treatments on patients’ health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.’s products and services are designed to help physicians improve patient monitoring and medical care while also improving their revenues.
Forward-Looking Statements
Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investor Relations Contact:
Olivia Giamanco
QHSLab, Inc.
(929) 379-6503
ir@usaqcorp.com
https://twitter.com/QHSLabInc
FAQ
What is the value of the grant QHSLab (USAQ) received for its allergic rhinitis study?
What digital tools will QHSLab (USAQ) be evaluating in the allergic rhinitis study?
Who is the Principal Investigator for QHSLab's (USAQ) allergic rhinitis study?
What is the ClinicalTrials.gov identifier for QHSLab's (USAQ) allergic rhinitis study?
